Delivery Order SPE2DR25D1103-SPE2DR26FD690
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,143.87 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,205.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on October 24, 2025, with an ultimate completion date of October 27, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with the federal government. The order will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,267.84 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on September 3, 2025, with completion by September 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 5 mg/0.5 mL pens totaling $20,561.10 with a completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $45,331.44 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on October 23, 2025, with completion scheduled for October 24, 2025. This competitive, non-set-aside delivery order employs firm fixed-price pricing and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The pharmaceutical distributor will perform this contract from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Zepbound 5 mg/0.5 mL pens at a ceiling value of $2,287.74. This contract represents a firm fixed price delivery order with an ultimate completion date of July 14, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,584.34 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, non-competitive delivery order is set to be completed by August 19, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,202.03 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-competitive, firm fixed-price delivery order is being fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,444.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 16, 2025, with completion scheduled for July 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single-unit pharmaceutical transaction under AmerisourceBergen's existing contract vehicle with DLA. The contractor, headquartered in Conshohocken, Pennsylvania, will fulfill this order at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,757.17 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award under the company's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FD690Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,895.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on October 30, 2025, with an ultimate completion date of October 31, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. Through this prime contract vehicle, AmerisourceBergen supplies a wide range of pharmaceutical products and medical supplies to support military healthcare programs and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates its established capability as a major pharmaceutical distributor serving critical federal medical procurement needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 10/30/25 |